Blocking the renin–angiotensin system: dual- versus mono-therapy

References

• Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary-artery disease – a workshop consensus statement. Am. Heart J.121(4), 1244–1263 (1991).
   PubMed Web of Science ®Google Scholar
• Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet365(9455), 217–223 (2005).
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet360(9349), 1903–1913 (2002).
   PubMed Web of Science ®Google Scholar
• Dielis AWJH, Smid M, Spronk HMH et al. The prothrombotic paradox of hypertension – role of the renin–angiotensin and kallikrein–kinin systems. Hypertension46(6), 1236–1242 (2005).
   PubMed Web of Science ®Google Scholar
• Peach MJ. Renin–angiotensin system – biochemistry and mechanisms of action. Physiol. Rev.57(2), 313–370 (1977).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure – the JNC 7 report. JAMA289(19), 2560–2572 (2003).
   PubMed Web of Science ®Google Scholar
• Joffe HV, Adler GK. Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. Hear Fail. Rev.10(1), 31–37 (2005).
   PubMed Web of Science ®Google Scholar
• Hollenberg NK, Fisher NDL, Price DA. Pathways for angiotensin II generation in intact human tissue – evidence from comparative pharmacological interruption of the renin system. Hypertension32(3), 387–392 (1998).
   PubMed Web of Science ®Google Scholar
• Wassmann S, Nickenig G. Pathophysiological regulation of the AT1-receptor and implications for vascular disease. J. Hypertens. Suppl.24(1), S15–S21 (2006).
   Google Scholar
• Nickenig G, Harrison DG. The AT1-type angiotensin receptor in oxidative stress and atherogenesis part I: oxidative stress and atherogenesis. Circulation105(3), 393–396 (2002).
   PubMed Web of Science ®Google Scholar
• Touyz RM. Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II. Exp. Physiol.90(4), 449–455 (2005).
   PubMed Web of Science ®Google Scholar
• Graninger M, Reiter R, Drucker C, Minar E, Jilma B. Angiotensin receptor blockade decreases markers of vascular inflammation. J. Cardiovasc. Pharm.44(3), 335–339 (2004).
   PubMed Web of Science ®Google Scholar
• Nickenig G, Harrison DG. The AT1-type angiotensin receptor in oxidative stress and atherogenesis – part II: AT1 receptor regulation. Circulation105(4), 530–536 (2002).
   PubMed Web of Science ®Google Scholar
• Perticone F, Ceravolo R, Pujia A et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation104(2), 191–196 (2001).
   PubMed Web of Science ®Google Scholar
• Schulman IH, Zhou MS, Raij L. Cross-talk between angiotensin II receptor types 1 and 2 – potential role in vascular remodeling in humans. Hypertension49(2), 270–271 (2007).
   PubMed Web of Science ®Google Scholar
• Steckelings UM, Kaschina E, Unger T. The AT2 receptor – a matter of love and hate. Peptides26(8), 1401–1409 (2005).
   PubMed Web of Science ®Google Scholar
• Pellacani A, Brunner HR, Nussberger J. Plasma kinins increase after angiotensin-converting enzyme-inhibition in human-subjects. Clin. Sci.87(5), 567–574 (1994).
   PubMed Web of Science ®Google Scholar
• Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation95(5), 1115–1118 (1997).
   PubMed Web of Science ®Google Scholar
• Hoppe UC. Treatment of heart failure with ACE inhibitors and β-blockers – what is next? AT1-receptor antagonists? Clin. Res. Cardiol.96(4), 196–198 (2007).
   PubMed Web of Science ®Google Scholar
• Ibrahim MM. RAS inhibition in hypertension. J. Hum. Hypertens.20(2), 101–108 (2006).
   PubMed Web of Science ®Google Scholar
• MacFadyen RJ, Lee AFC, Morton JJ, Pringle SD, Struthers AD. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart82(1), 57–61 (1999).
   PubMed Web of Science ®Google Scholar
• Schieffer B, Schieffer E, Hilfiker-Kleiner D et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques – potential implications for inflammation and plaque instability. Circulation101(12), 1372–1378 (2000).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med.342(3), 145–153 (2000).
   PubMed Web of Science ®Google Scholar
• Fox KM, Bertrand M, Ferrari R et al. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet362(9386), 782–788 (2003).
   PubMed Web of Science ®Google Scholar
• Braunwald E, Pfeffer MA, Domanski M et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med.351(20), 2058–2068 (2004).
   PubMed Web of Science ®Google Scholar
• Pepine C, Probstfield J. A HOPE for PEACE? Update on the role of ACE inhibition in CAD patients. Vasc. Biol. Clin. Pract.6(3) (2004).
   Google Scholar
• Pitt B, O’Neill B, Feldman R et al. The QUinapril Ischemic Event Trial (OUIET): Evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am. J. Cardiol.87(9), 1058–1063 (2001).
   PubMed Web of Science ®Google Scholar
• Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet368(9535), 581–588 (2006).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med.358(15), 1547–1559 (2008).
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med.349(20), 1893–1906 (2003).
   PubMed Web of Science ®Google Scholar
• Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. Circulation112(12), E154–E235 (2005).
   PubMed Web of Science ®Google Scholar
• AIRE Study Investigators. The Acute Infarction Ramipril Efficacy (AIRE) study. Circulation88(4), 394–394 (1993).
   Google Scholar
• Swedberg K. Effects of enalapril on mortality in severe congestive-heart-failure – results of the cooperative-north-scandinavian-enalapril-survival-study (consensus). N. Engl. J. Med.316(23), 1429–1435 (1987).
   PubMed Web of Science ®Google Scholar
• Flather MD, Yusuf S, Kober L et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet355(9215), 1575–1581 (2000).
   PubMed Web of Science ®Google Scholar
• Yusuf S. Effect of enalapril on survival in patients with reduced left-ventricular ejection fractions and congestive-heart-failure. N. Engl. J. Med.325(5), 293–302 (1991).
   PubMed Web of Science ®Google Scholar
• Nicklas JM, Pitt B, Timmis G et al. Effect of enalapril on mortality and the development of heart-failure in asymptomatic patients with reduced left-ventricular ejection fractions. N. Engl. J. Med.327(10), 685–691 (1992).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Pepine CJ, Garces C et al. Effect of enalapril on myocardial-infarction and unstable angina in patients with low ejection fractions. Lancet340(8829), 1173–1178 (1992).
   PubMed Web of Science ®Google Scholar
• Ball SG, Cowan JC, Winter C et al. Effect of ramipril on mortality and morbidity of survivors of acute myocardial-infarction with clinical-evidence of heart-failure. Lancet342(8875), 821–828 (1993).
   PubMed Web of Science ®Google Scholar
• Torp-Pedersen C, Kober L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. Lancet354(9172), 9–12 (1999).
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med.345(23), 1667–1675 (2001).
   PubMed Web of Science ®Google Scholar
• Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet362(9386), 772–776 (2003).
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet362(9386), 759–766 (2003).
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet362(9386), 767–771 (2003).
   PubMed Web of Science ®Google Scholar
• Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial – the Losartan Heart Failure Survival Study ELITE II. Lancet355(9215), 1582–1587 (2000).
   PubMed Web of Science ®Google Scholar
• Bosch J, Yusuf S, Pogue J et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ324(7339), 699–702 (2002).
   PubMed Web of Science ®Google Scholar
• Lithell H, Hansson L, Skoog I et al. The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. J. Hypertens.22(8), 1605–1612 (2004).
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet358(9292), 1556–1556 (2001).
   Google Scholar
• Yusuf S, Diener H, Sacco RL et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N. Engl. J. Med.359(12), 1225–1237 (2008).
   PubMed Web of Science ®Google Scholar
• Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet353(9153), 611–616 (1999).
   PubMed Web of Science ®Google Scholar
• Stearne MR, Palmer SL, Hammersley MS et al. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 39. BMJ317(7160), 713–720 (1998).
   PubMedGoogle Scholar
• Schmieder RE. Endothelial dysfunction: how can one intervene at the beginning of the cardiovascular continuum? J. Hypertens.24, S31–S35 (2006).
   Google Scholar
• Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N. Engl. J. Med.345(12), 870–878 (2001).
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in Type 2 diabetes. N. Engl. J. Med.351(19), 1941–1951 (2004).
   PubMed Web of Science ®Google Scholar
• Agodoa LY, Appel L, Bakris GL et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis – a randomized controlled trial. JAMA285(21), 2719–2728 (2001).
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med.345(12), 861–869 (2001).
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med.345(12), 851–860 (2001).
   PubMed Web of Science ®Google Scholar
• Barnett AH, Bain SC, Bouter P et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in Type 2 diabetes and nephropathy. N. Engl. J. Med.351(19), 1952–1961 (2004).
   PubMed Web of Science ®Google Scholar
• Mann JF, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet372(9638), 547–553 (2008).
   PubMed Web of Science ®Google Scholar
• Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in Type 2 diabetes and nephropathy. AVOID Study investigators. N. Engl. J. Med.358, 2433–2446 (2008).
   PubMed Web of Science ®Google Scholar